India Share Brokers | Equity Trading India | Derivative Trading in India | Share Brokers in India

Markets Navigation

Company Info.

Bal Pharma Ltd.

Income Statement - Consolidated

Market Cap.(`)	194.60 Cr.	P/BV	2.83	Book Value (`)	43.21
52 Week High/Low ( ` )	158/78	FV/ML	10/1	P/E(X)	26.33
Book Closure	25/09/2024	EPS (`)	4.64	Div Yield (%)	0.98

(` in Crs.)

You can view the Consolidated Income Statement for the last 5 years.

Particulars	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
Months	12	12	12	12	12
Source Of Info (AR = Annual Report, PR = Press Release)	AR	AR	AR	AR	AR
FaceValue	10.00	10.00	10.00	10.00	10.00


INCOME
Revenue From Operations [Net]	326.35	304.22	279.70	246.94	167.67
Other Operating Revenues	12.87	0.00	1.52	3.58	3.42
Total Operating Revenues	339.22	304.22	281.21	250.53	171.09

Other Income	2.85	0.94	5.15	1.14	1.84
Total Revenue	342.07	305.16	286.37	251.67	172.93

EXPENSES
Cost Of Materials Consumed	181.58	179.19	163.99	135.47	72.20
Purchase Of Stock-In Trade	11.24	11.45	8.43	10.43	8.54
Changes In Inventories Of FG,WIP And Stock-In Trade	-1.06	-17.87	-4.89	5.05	3.38
Employee Benefit Expenses	60.38	55.30	47.25	41.88	50.43
Finance Costs	15.26	12.19	10.41	11.97	12.45
Depreciation And Amortisation Expenses	10.07	9.13	9.04	9.52	7.68
Other Expenses	55.56	51.03	42.96	33.25	31.78
Total Expenses	333.02	300.41	277.18	247.56	186.46

Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax	9.05	4.75	9.18	4.10	-13.53

Profit/Loss Before Tax	9.05	4.75	9.18	4.10	-13.53

Tax Expenses-Continued Operations
Current Tax	3.20	2.58	4.48	0.38	0.00
Deferred Tax	0.85	0.10	-1.94	-0.99	-0.49
Tax For Earlier Years	-2.45	-0.55	0.94	0.00	-0.15
Total Tax Expenses	1.60	2.13	3.48	-0.61	-0.64
Profit/Loss After Tax And Before ExtraOrdinary Items	7.45	2.62	5.70	4.71	-12.89

Profit/Loss From Continuing Operations	7.45	2.62	5.70	4.71	-12.89

Profit/Loss For The Period	7.45	2.62	5.70	4.71	-12.89

Minority Interest	-0.05	-0.05	-0.09	0.03	0.67
Consolidated Profit/Loss After MI And Associates	7.39	2.57	5.61	4.74	-12.22

OTHER INFORMATION

EARNINGS PER SHARE
Basic EPS (Rs.)	4.94	1.67	3.79	3.34	-9.10
Diluted EPS (Rs.)	4.96	1.68	3.79	3.34	-9.10

DIVIDEND AND DIVIDEND PERCENTAGE
Equity Share Dividend	1.57	1.56	1.48	0.00	1.42
Tax On Dividend	0.00	0.00	0.00	0.00	0.29

Bal Pharma Ltd.

Balance Sheet - Consolidated

Market Cap.(`)	194.60 Cr.	P/BV	2.83	Book Value (`)	43.21
52 Week High/Low ( ` )	158/78	FV/ML	10/1	P/E(X)	26.33
Book Closure	25/09/2024	EPS (`)	4.64	Div Yield (%)	0.98

(` in Crs.)

You can view the Consolidated Balance Sheet for the last 5 years.

Particulars	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
Months	12	12	12	12	12
Source Of Info (AR = Annual Report, PR = Press Release)	AR	AR	AR	AR	AR
FaceValue	10.00	10.00	10.00	10.00	10.00
No. of Equity Shares (in Lacs)	158.04	156.90	148.24	148.24	141.72

EQUITIES AND LIABILITIES
SHAREHOLDER'S FUNDS
Equity Share Capital	15.80	15.69	14.82	14.82	14.17
Total Share Capital	15.80	15.69	14.82	14.82	14.17

Reserves and Surplus	53.49	48.10	42.87	37.82	38.25
Total Reserves and Surplus	53.49	48.10	42.87	37.82	38.25
Money Received Against Share Warrants	0.00	0.00	0.94	0.94	0.00
Total Shareholders Funds	69.29	63.79	58.63	53.58	52.43
Minority Interest	-0.03	-0.09	-0.13	-0.23	-7.09

NON-CURRENT LIABILITIES
Long Term Borrowings	36.35	30.52	27.01	23.93	23.15
Deferred Tax Liabilities [Net]	3.96	2.87	0.60	2.63	3.58
Other Long Term Liabilities	1.83	1.68	4.08	3.56	3.21
Long Term Provisions	5.09	5.07	4.69	4.07	3.62
Total Non-Current Liabilities	47.22	40.14	36.40	34.19	33.56

CURRENT LIABILITIES
Short Term Borrowings	103.25	100.48	70.75	80.82	89.63
Trade Payables	77.46	78.92	65.56	47.17	38.67
Other Current Liabilities	21.38	29.30	28.60	23.89	30.69
Short Term Provisions	0.95	0.64	0.73	0.66	0.50
Total Current Liabilities	203.04	209.33	165.64	152.53	159.49

Total Capital And Liabilities	319.53	313.17	260.53	240.08	238.39

ASSETS
NON-CURRENT ASSETS
Tangible Assets	61.61	62.18	55.57	57.51	60.45
Intangible Assets	11.38	10.46	7.99	7.25	6.43
Capital Work-In-Progress	0.47	0.00	1.61	0.00	3.32
Fixed Assets	73.46	72.64	65.18	64.76	70.20
Goodwill On Consolidation	3.83	3.83	3.83	3.83	3.83
Deferred Tax Assets [Net]	2.41	2.17	0.00	0.00	0.00
Long Term Loans And Advances	0.12	0.10	0.40	0.38	0.29
Other Non-Current Assets	5.56	6.29	6.56	6.96	2.94
Total Non-Current Assets	85.38	85.02	75.96	75.93	77.26


CURRENT ASSETS
Current Investments	6.76	0.00	0.00	0.00	0.00
Inventories	87.81	98.01	74.40	60.39	67.71
Trade Receivables	99.62	93.98	75.31	67.20	49.60
Cash And Cash Equivalents	13.29	7.61	5.39	3.85	3.13
Short Term Loans And Advances	1.37	0.96	2.37	2.06	2.21
OtherCurrentAssets	25.30	27.60	27.10	30.65	38.48
Total Current Assets	234.15	228.16	184.57	164.15	161.14

Total Assets	319.53	313.17	260.53	240.08	238.39

OTHER INFORMATION

CONTINGENT LIABILITIES, COMMITMENTS
Contingent Liabilities	16.96	0.00	0.00	4.34	12.99

BONUS DETAILS
Bonus Equity Share Capital	3.04	3.04	3.04	3.04	3.04

Attention Investors : “Prevent unauthorized transactions in your account ? Update your Mobile Numbers/Email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your Mobile/Email at the end of the day. Issued in the interest of Investors” ***** No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorize your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. | | ***** KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary. | "Revised guidelines on margin collection ==> 1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. | 2. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. | 3. Pay 20% upfront margin of the transaction value to trade in cash market segment. | 4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard. | 5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month. .......... Issued in the interest of Investors" | ***** MEMBERS : SEBI Regn. No: NSE, BSE: INZ000176636 ; MCX : INZ000057535; SEBI Research Analyst Regn No: INH200000337; AMFI Regn No. 77624; Depository Participant : CDSL : IN-DP-CDSL-379-2006 DP ID : 12047600 | For any Grievance mail to : grievance@sharewealthindia.com | For any DP Grievance mail to : dpgrievance@sharewealthindia.com. | Grievance with SEBI : https://scores.gov.in/scores/Welcome.html

Share Wealth

Bal Pharma Ltd.

Income Statement - Consolidated

Bal Pharma Ltd.

Balance Sheet - Consolidated